Bafna Pharmaceuticals P/E Ratio
Bafna Pharmaceuticals P/E ratio. Bafna Pharmaceuticals (BAFNAPH) P/E ratio is not applicable — EPS (TTM) ₹-15.52, 3 consecutive loss quarters. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company has reported losses in the last 3 quarters. P/E ratio is not applicable during loss periods.
Consecutive Loss Quarters: 3
Current EPS: ₹-15.52
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Sept 2019 | -0.25 | -1 | Loss |
| Jun 2019 | -0.90 | -2 | Loss |
| Sept 2018 | -0.80 | -1 | Loss |
Healthcare Peers with Valid P/E Ratios — BAFNAPH Comparison
Healthcare sector average P/E 56.19, median 32.5 — BAFNAPH excluded (negative EPS).
Sector Average PE
56.19
Sector Median PE
32.5
Lowest PE
2.04
Profitable Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Bafna Pharmaceuticals share price chart.
- Examine BAFNAPH quarterly performance for recent quarterly revenue, profit and EPS trends.
- Also explore BAFNAPH share price history to track price trends across different timeframes.